

Potential food allergens in medications

John M. Kelso, MD *San Diego, Calif*

INFORMATION FOR CATEGORY 1 CME CREDIT

Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions.

Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.jacionline.org. The accompanying tests may only be submitted online at www.jacionline.org. Fax or other copies will not be accepted.

Date of Original Release: June 2014. Credit may be obtained for these courses until May 31, 2015.

Copyright Statement: Copyright © 2014–2015. All rights reserved.

Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease.

Target Audience: Physicians and researchers within the field of allergic disease.

Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates this journal-based CME activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

List of Design Committee Members: John M. Kelso, MD

Activity Objectives

1. To describe which food-derived substances are used as pharmaceutical excipients in which medications.
2. To review published data regarding the safety of administration of these medications to recipients with food allergy.
3. To prescribe these medications to most patients with food allergies.
4. To investigate potential allergy to the food component if a particular patient has had an apparent allergic reaction to a medication containing it.

Recognition of Commercial Support: This CME activity has not received external commercial support.

Disclosure of Significant Relationships with Relevant Commercial

Companies/Organizations: J. M. Kelso is a board member of the American Academy of Allergy, Asthma & Immunology (AAAAI); is employed by Scripps Clinic; and has received payment for lectures from the AAAAI, the American College of Allergy, Asthma & Immunology, the American Academy of Pediatrics, the American College of Physicians, and Symposia Medicus.

Excipients are substances in pharmaceuticals other than the active ingredients. Some excipients are foods or substances derived from foods, raising the possibility that these substances would pose a hazard to patients with food allergy. This review describes which food-derived substances are used as pharmaceutical excipients in which medications and reviews published data regarding the safety of the administration of these medications to recipients with food allergy. Such reactions are rare, usually because the amount of food protein is not present in a large enough quantity to elicit a reaction. When a food protein appears as an unintentional contaminant, the amount, if any, that is present might be variable and might elicit reactions only from some lots of medication or only in some patients. In most circumstances these medications should not be routinely withheld from patients who have particular food allergies because most will tolerate the medications uneventfully. However, if a particular patient has had an apparent allergic reaction to the medication, potential allergy to the food component should be investigated. (*J Allergy Clin Immunol* 2014;133:1509–18.)

Key words: Food allergy, medication allergy, vaccine allergy

Abbreviations used

- IIV: Inactivated influenza vaccine
ILE: Intravenous lipid emulsion
LAIV: Live attenuated influenza vaccine
TPN: Total parenteral nutrition

Discuss this article on the JACI Journal Club blog: www.jaci-online.blogspot.com.

Excipients are all of the substances found in pharmaceuticals other than the active ingredients. These substances are added to “aid the manufacturing process, to protect, support or enhance stability, or for bioavailability or patient acceptability.”¹ Some pharmaceutical excipients are foods or, more often, substances derived from foods, raising the possibility that these substances would pose a hazard to patients with food allergy.² The purpose of this publication is to describe which food-derived substances are used as pharmaceutical excipients in which medications (Table I)^{3–171} and to review published data regarding the safety of the administration of these medications to recipients with food allergy.

Virtually all food allergens that generate IgE-mediated responses are proteins. In some cases the food excipients in medications are in fact proteins and thus capable of being allergenic. The amount and nature of (eg, how thoroughly hydrolyzed) these proteins might influence their allergenic potential. However, in many other cases the food excipient in the medication is a fat or carbohydrate and thus would not be expected to be allergenic. In these cases the excipient would have

From the Division of Allergy, Asthma and Immunology, Scripps Clinic.

Received for publication January 25, 2014; revised February 18, 2014; accepted for publication March 12, 2014.

Corresponding author: John M. Kelso, MD, Division of Allergy, Asthma and Immunology, Scripps Clinic, 3811 Valley Center Dr, San Diego, CA 92130. E-mail: kelso.john@scrippshealth.org.

0091-6749/\$36.00

© 2014 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaci.2014.03.011>

TABLE I. Potential food allergens in medicines

Food	Excipients	Drugs
Egg	Egg protein/ovalbumin	<ul style="list-style-type: none"> Interferon Alfa-n3* Probiotics¹⁴³ Vaccines³: <ul style="list-style-type: none"> influenza* (IIV,³¹⁻⁵⁸ LAIV) MMR^{*4-30} Rabies (PCEC) Yellow fever*
	Egg lecithin/phospholipids	<ul style="list-style-type: none"> Emulsions: <ul style="list-style-type: none"> Clevidipine* Fat emulsions^{62,63} Propofol^{*64-81} Tablets: <ul style="list-style-type: none"> Diphenhydramine Denofibrate Ibuprofen Multivitamin Rosiglitazone Verteporfin injection⁸²
Fish	Protamine	<ul style="list-style-type: none"> Protamine injection^{*83-91} NPH insulin
	Fish oil	<ul style="list-style-type: none"> Fish oil supplements⁹⁴ Some multivitamins
Gelatin	Gelatin	<ul style="list-style-type: none"> Many capsules and tablets^{97,98} Benzocaine oral gel Chloral hydrate suppositories⁹⁹ Corticotropin repository injection Erythropoietin¹⁰⁰ Hemostatic sponges^{101,102} Nicotine chewing gum Plasma volume expanders¹⁰³⁻¹²⁰ Sulfur colloid injection¹²¹ Vaccines³: <ul style="list-style-type: none"> Influenza (Fluzone,¹³⁵ FluMist*) Japanese encephalitis^{125,127,133} MMR^{*95,96,122,123,126,128,130,132,134,136,137} MMRV* Rabies (RabAvert)* Tick-borne encephalitis¹³¹ Typhoid vaccine, live oral Varicella^{*123,124,129,130,138} Yellow fever* Zoster*
	Casamino acids	<ul style="list-style-type: none"> Vaccines^{104,141}: <ul style="list-style-type: none"> DTaP (Daptacel) DTaP-IPV/Hib (Pentacel) Meningococcal (Menomune) Pneumococcal (PCV13 – Prevnar 13) Td (Tenivac) Tdap (Adacel)
Milk	Casein	<ul style="list-style-type: none"> Cefditoren tablets* Miconazole tablets* Probiotics¹⁴² Vaccines^{140,141}: <ul style="list-style-type: none"> DTaP (Infanrix) DTaP+HepB+IPV (Pediarix) DTaP+IPV (Kinrix) Tdap (Boostrix) Typhoid (Vivotif)
	Cow's milk	<ul style="list-style-type: none"> Some psyllium solutions Tums Smoothies tablets
Lactalbumin		<ul style="list-style-type: none"> OPV¹⁴³

(Continued)

TABLE I. (Continued)

Food	Excipients	Drugs
Lactose ¹⁴⁴		<ul style="list-style-type: none"> Many tablets, capsules, granules, and lyophilized powders¹⁴⁵ Some psyllium solutions DPIs: device name (drug name/s)¹⁴⁶⁻¹⁴⁸ <ul style="list-style-type: none"> Aerolizer (Foradil)* Diskus (Advair, Flovent, Ventolin)* Flexhaler (Pulmicort)* HandiHaler (Spiriva)* Neohaler (Arcapta)* Pressair (Tudorza)* Rotahaler (Tiova) Turbuhaler/Turbohaler (Bricanyl, Oxis*, Pulmicort*, Symbicort*) Twisthaler (Asmanex)*
	Lactulose	<ul style="list-style-type: none"> Lactulose solution¹⁴⁹
Peanut	Peanut oil	<ul style="list-style-type: none"> Dimercaprol injection* Progesterone capsules* Valproic acid capsules
	Pine nut	<ul style="list-style-type: none"> Fluoride tooth varnish¹⁵⁰
Sesame	Sesame oil	<ul style="list-style-type: none"> Dronabinol capsules* Estradiol injection Fluphenazine decanoate injection Haloperidol decanoate injection Nandrolone decanoate injection Progesterone injection* Testosterone injection
	Shellfish	<ul style="list-style-type: none"> Dietary supplements for arthritis¹⁵¹⁻¹⁵⁶
Soy	Glucosamine	<ul style="list-style-type: none"> Radiocontrast media¹⁵⁷
	Iodine	<ul style="list-style-type: none"> MDIs¹⁶¹⁻¹⁶⁶ <ul style="list-style-type: none"> Atrovent Combivent*
Soy lecithin		<ul style="list-style-type: none"> Emulsions: <ul style="list-style-type: none"> Clevidipine* Fat emulsions^{158-160,167-171} Propofol^{*64-81}
	Soy oil	<ul style="list-style-type: none"> Amphotericin B liposome Doxorubicin liposome
Soy phosphatidylcholine		<ul style="list-style-type: none"> Tums Smoothies tablets
	Soybean	

Note that hundreds of nutritional supplements and homeopathic remedies not regulated by the US Food and Drug Administration also contain food ingredients. *DPI*, Dry powder inhaler; *MDI*, metered-dose inhaler; *MMR*, measles-mumps-rubella; *PCEC*, purified chick embryo cell.

*The package insert lists food allergy as a warning or contraindication.

to be contaminated with protein for an allergen to be present. This type of contamination might well be random or variable. This variability in the amount and nature of food protein present in medications by design or by accident means that there could be great lot-to-lot variability in the presence of these proteins. Individual patients would also be expected to vary quite widely in susceptibility to allergic reactions with exposure to these food proteins in medications, depending on the amount of IgE antibody generated against the particular food allergen and particular epitopes on the food allergen.

EGG

Egg protein/ovalbumin

Vaccines. Measles, mumps, and purified chick embryo cell rabies vaccines are grown in chick embryo fibroblast cultures and

contain negligible or no egg protein. Thus despite some discussion in the warnings sections of the package inserts, measles-mumps-rubella and purified chick embryo cell rabies vaccine can be administered to recipients with egg allergy in the usual manner.^{3-30,173}

Egg protein is present in higher amounts in influenza and yellow fever vaccines and in theory could cause reactions in patients with egg allergy. However, in 27 published studies, collectively, 4172 patients with egg allergy received 4729 doses of inactivated influenza vaccine (IIV) with no cases of anaphylaxis, including 513 with severe allergy who uneventfully received 597 doses.³¹⁻⁵⁸ This is likely due to the very low amount of egg protein present in these vaccines.^{3,59-61} The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices and the American Academy of Pediatrics' Committee on Infectious Diseases recommend that persons with egg allergy receive IIV as a single dose without prior vaccine skin testing and be observed for 30 minutes afterward for any possible allergic reaction.^{174,175} If the reaction to the ingestion of eggs is hives only, the vaccine can be administered in a primary care setting, whereas if the reaction to the ingestion of eggs is more severe, the vaccine should be administered in an allergist's office. Two new IIVs not grown in eggs have been approved for patients 18 years and older: Flucelvax,¹⁷⁶ which is prepared from virus propagated in cell culture, and Flublok,¹⁷⁷ which consists of recombinant hemagglutinin proteins produced in an insect cell line. For patients with egg allergy 18 years of age and older, either egg-based or egg-free IIV can be used. Live attenuated influenza vaccine (LAIV) also contains a very low amount of egg protein.³ Because there are no published studies on the safety of LAIV in recipients with egg allergy, guidelines recommend the use of IIV in these patients,^{174,175,178} although LAIV would be expected to have a safety profile similar to that of IIV.

Per the yellow fever vaccine package insert,¹⁷⁹ recipients with egg allergy should be skin tested with the vaccine before administration. If results are negative, the vaccine can be given in the usual manner, but the patient should be observed for 30 minutes afterward. If the vaccine skin test result is positive, the vaccine can be administered in graded doses under observation.

Egg lecithin/phospholipids

Lecithin is a fatty substance occurring in animal and plant tissues composed of phosphoric acid, choline, fatty acids, glycerol, glycolipids, triglycerides, and phospholipids. Commercial sources of lecithins for use in pharmaceutical agents include soybean oil and egg yolk, and these products contain some residual protein,¹⁸⁰ although reports of allergic reactions to them are rare and largely unsubstantiated, and thus patients with soy and egg allergy need not avoid them.

Intravenous lipid emulsions. Some intravenous lipid emulsions (ILEs) contain 1.2% egg yolk phospholipids.⁶² There is a single case report of a child having diffuse pruritus after 14 days of treatment with ILEs who had IgE antibody to egg yolk, but no testing with the ILEs was performed.⁶³ Most purported allergic reactions to ILEs are in relation to soy, as below.

Propofol. Propofol is an intravenous sedative-hypnotic agent used in anesthesia. It is formulated in a fat emulsion containing

soybean oil (100 mg/mL) and egg lecithin (12 mg/mL).^{181,182} There are numerous reports of urticarial or anaphylactic reactions to propofol.⁶⁴⁻⁸¹ Although most reports of anaphylaxis to propofol have occurred in patients without egg allergy, 2 reports have implicated egg as a possible allergen,^{73,77} although no testing was done to support this contention. Furthermore, the vast majority of patients with egg allergy receive propofol uneventfully.⁸¹ Some reports of apparent allergic reactions to propofol have included positive immediate-type skin test results or serum specific IgE antibody assays, suggesting a possible IgE-mediated mechanism.^{66,70-72,74,78,80} Intradermal skin test concentrations as high as 1 mg/mL have been reported to be nonirritating.⁷¹ However, the conclusion that cases of anaphylaxis are due to an IgE-mediated reaction to propofol are complicated by several factors, including that many patients have had such reactions after receiving the drug for the first time and that many such cases have occurred with simultaneous administration of other drugs that can cause or worsen anaphylaxis, including muscle relaxants and opioid analgesics.⁷¹ Thus although it is clear that propofol can cause anaphylactic reactions, the mechanism of these reactions is unclear and appears unrelated to egg allergy.

Verteporfin. There is a single case report of anaphylaxis after infusion of verteporfin used to treat macular degeneration.⁸² The medication contains egg phosphatidylglycerol, but there is no mention of egg allergy in the patient.

FISH

Protamine

Protamines are small proteins involved in sperm biology.¹⁸³ Protamine for pharmaceutical use is isolated from salmon testes and is used to reverse the effects of heparin and complexed to some insulins to delay absorption.¹⁸⁴ Urticarial and anaphylactic reactions to protamine have been reported.⁸³⁻⁹¹ Some reports have suggested that these reactions might be due to cross-reactions with other fish proteins,^{83,84,88} although no testing was done to support this contention. Furthermore, ELISA inhibition studies with sera from patients with salmon allergy showed no inhibition with protamine, and serum from a patient with protamine allergy showed no inhibition with salmon.⁹² Also, most patients with fish allergy tolerate protamine uneventfully.⁸⁵ Some reports of apparent allergic reactions to protamine have included positive immediate-type skin test or serum specific IgE antibody assay results, suggesting a possible IgE-mediated mechanism.⁸⁶ However, results of protamine skin tests and serum specific IgE antibody assays correlate poorly with each other, and both are poorly correlated with reactions to protamine; that is, most patients with positive test results do not react to protamine, and most patients with reactions have negative test results.^{87,93} Thus although it is clear that protamine can cause anaphylactic reactions, the mechanism of these reactions is unclear and appears unrelated to fish allergy, and thus patients with fish allergy need not avoid protamine.

Fish oil

Fish oils are generally highly refined and should not contain fish protein.¹⁸⁵ Patients with fish allergy have been challenged

with fish oils and show no reaction.⁹⁴ Thus patients with fish allergy need not avoid fish oil.

GELATIN

Gelatin is produced by partial hydrolysis of collagen extracted from connective tissues of animals, such as cows or pigs. Thus it contains potentially allergenic protein fragments. Bovine and porcine gelatins are extensively cross-reactive.^{95,96,186,187} There are many well-documented cases of IgE-mediated anaphylactic reactions to the gelatin-containing products listed below, and patients with gelatin allergy should generally avoid them. Most reactions involve parenteral exposure. Oral exposure to gelatin-containing capsules has only rarely been reported to cause reactions, and patients with gelatin allergy are generally able to tolerate these.

Capsules

Despite their widespread use, there are only 2 case reports of allergic reactions to gelatin capsules.^{97,98}

Suppositories

Anaphylaxis in 10 children to gelatin-containing chloral hydrate rectal suppositories has been reported, with all of these children having serum specific IgE to gelatin.⁹⁹

Erythropoietin

There is a single case report of a patient who had anaphylaxis after infusion of an erythropoietin preparation containing gelatin but who tolerated a non-gelatin-containing preparation of the same medication.¹⁰⁰ She was subsequently found to have increased specific IgE levels to gelatin.

Hemostatic sponges

Gelfoam (Pfizer, New York, NY) is an absorbable gelatin sponge prepared from purified porcine skin applied to bleeding surfaces as a hemostatic agent.¹⁸⁸ Two cases of intraoperative anaphylaxis have been attributed to allergic reactions to this material, and this hypothesis was supported by increased serum specific IgE levels to gelatin.^{101,102}

Plasma volume expanders

Several gelatin solutions are used outside the United States as colloid plasma volume expanders, including succinylated gelatin or modified fluid gelatin, urea-linked gelatin or polygeline, and oxypolygelatin.¹⁸⁹ There are many reports of anaphylaxis to the infusion of these materials,¹⁰³⁻¹²⁰ including fatalities.^{108,110} The rate of such reactions is reported to be 0.075% of units infused.¹¹² Many of these reports have demonstrated positive immediate-type allergy skin test results to the gelatin solutions,^{103,104,112,115,117,118} and 1 report demonstrated positive basophil activation as well.¹¹⁸ Gelatin solution infusions can induce histamine release in a small percentage of healthy subjects without prior exposure, although typically without clinical consequence or causing hives only, suggesting that some reactions might be due to direct mast cell degranulation.^{105,109,111}

TABLE II. Gelatin content of US vaccines, 2014

Vaccine	Gelatin content
Influenza (Fluzone [trivalent only]; Sanofi Pasteur, Lyon, France)	250 µg per 0.5-mL dose
Influenza (FluMist; MedImmune Vaccines, Gaithersburg, Md)	2,000 µg per 0.2-mL dose
Measles, Mumps, Rubella (MMR2; Merck, Whitehouse Station, NJ)	14,500 µg per 0.5-mL dose
Measles, Mumps, Rubella, Varicella (ProQuad, Merck)	11,000 µg per 0.5-mL dose
Rabies (RabAvert; Novartis, Emeryville, Calif)	12,000 µg per 1.0-mL dose
Typhoid Vaccine Live Oral Ty21a (VIVOTIF; Berna, Coral Gables, Fla)	Capsule
Varicella (VARIVAX, Merck)	12,500 µg per 0.5-mL dose
Yellow Fever (YF-VAX, Sanofi Pasteur)	7,500 µg per 0.5-mL dose
Zoster (ZOSTAVAX, Merck)	15,580 µg per 0.65-mL dose

Sulfur colloid injection

There is a single case report of an anaphylactic reaction after the infusion of a technetium sulfur colloid stabilized with gelatin; however, no testing was done to determine the potential allergen.¹²¹

Vaccines

A number of (mostly live viral) vaccines contain gelatin as a stabilizer (Table II).³ There are many well-documented cases of anaphylaxis to gelatin-containing vaccines in recipients subsequently determined to have serum specific anti-gelatin IgE.^{95,96,122-135} Most such reactions have occurred after injection of vaccines that contain milligram quantities of gelatin, namely measles-mumps-rubella,^{95,96,122,132,134} varicella,^{123,124,129} and Japanese encephalitis^{125,127,133} vaccines. Some patients with gelatin allergy tolerate the ingestion of gelatin yet have systemic allergic reactions to gelatin injected in a vaccine,⁹⁵ presumably because digestion allows for the proteins to be broken down into fragments too small to remain allergenic before absorption. However, patients with histories of reactions to the ingestion of gelatin confirmed by skin tests or specific IgE assays to gelatin should undergo vaccine skin testing before receipt of gelatin-containing vaccines.³ Most patients with gelatin allergy generate IgE antibodies to a 10-amino-acid epitope on the α -2 chain of type I collagen, a sequence not found on human type I collagen.^{190,191} The incidence of gelatin allergy appears to be higher in Japan,¹³⁶ perhaps because of an HLA type (DR 9) common in Japanese subjects.¹⁹² In Japan vaccine manufacturers removed gelatin or changed to a less allergenic (more thoroughly hydrolyzed) gelatin in vaccines, after which there was a dramatic decrease in reports of anaphylaxis associated with these vaccines.^{137,138} Vaccines in many other countries, including the United States, continue to contain gelatin (Table II).

MILK

Reports of allergic reactions to pharmaceuticals in patients with milk allergy are rare, and in general, such patients need not avoid the products below.

Casamino acids

Vaccines. A series of 8 patients with high-level milk allergy has been reported who had anaphylactic reactions after receiving

DTaP or Tdap vaccines.¹⁴⁰ The growth media for these vaccines contain casamino acids derived from casein, and nanogram quantities of casein are present in the vaccines, which might be sufficient to trigger reactions in exquisitely sensitive patients. Other authors have challenged this association and noted no safety signal in the Vaccine Adverse Event Reporting System database among patients with milk allergy receiving these vaccines.¹⁴¹

Casein

Probiotics. There is a single case report of an anaphylactic reaction to a probiotic in a child with milk and egg allergy.¹⁴² Cow's milk is the culture medium for most probiotics. The child had a positive skin prick test result with the suspect probiotic, and several probiotics analyzed contained milk and, in some cases, egg protein.

Lactalbumin

Vaccines. A series of 4 children with milk allergy has been reported who had immediate-type allergic reactions after oral polio vaccine.¹⁴³ The Italian manufacturer of the vaccine listed α -lactalbumin as an ingredient, which was confirmed by using ELISA. Patient IgE directed against the vaccine was partially inhibited by α -lactalbumin.

Lactose

Lactose is milk sugar purified from cow's milk. Pharmaceutical-grade lactose is generally thought to be free of contaminating milk proteins. Twenty-four children with positive double-blind, placebo-controlled food challenge results to milk ingestion and positive skin prick test responses and serum specific IgE assay results to milk had negative skin test and oral challenge results with lactose.¹⁴⁴ Immunoblotting did not reveal the presence of any protein in the lactose preparations. Nonetheless, on rare occasions, lactose can be contaminated by milk proteins, as below.

Methylprednisolone injections. A series of 2 patients with high-level milk allergy has been reported who had urticarial reactions after receiving lactose-containing methylprednisolone injections.¹⁴⁵ The patients had positive immediate-type skin test results to the suspect medication but not to a lactose-free preparation of methylprednisolone. Assay of the lactose-containing methylprednisolone revealed nanogram quantities of β -lactoglobulin.

Dry powder inhalers. Most dry powder inhalers containing medications to treat asthma or chronic obstructive pulmonary disease contain lactose to improve drug delivery and to impart taste to indicate dose delivery.¹⁴⁶ A child with severe milk allergy has been reported who had chest tightness and a decrease in FEV₁ and blood pressure immediately after an inhalation from a dry powder inhaler containing lactose.¹⁴⁶ The patient had a positive immediate-type skin test result to the suspect lot of medication but not to a different lot. Some milk proteins were detected in some other dry powder inhalers. Similar reactions have been reported in 1 other child with milk allergy¹⁴⁷ and 1 other adult with milk allergy.¹⁴⁸ This is apparently quite a rare phenomenon given the large number of children with milk allergy who use lactose-containing dry powder inhalers uneventfully.

Lactulose

Lactulose is a synthetic nondigestible disaccharide produced by isomerization of lactose used to treat constipation. There is a single case report of an apparent allergic reaction in a child with milk allergy after ingestion of lactulose syrup, but no testing was done to demonstrate that the reaction was due to any milk protein that could possibly have been contaminating the medication.¹⁴⁹

PEANUT

Peanut oil

The package inserts for dimercaprol for injection, progesterone capsules, and valproic acid capsules list peanut oil as an ingredient, and the former 2 drugs also list peanut allergy as a precaution. However, there are no reports of allergic reactions to peanut oil in these medications, presumably because pure peanut oil is not allergenic.¹⁹³

PINE NUT

Rosin

Rosin, also called colophony, is a solid form of resin obtained from pine tree stumps. Some fluoride tooth varnish contains rosin.¹⁵⁰ Some patients with allergy to pine nuts have questioned whether it would be safe to use pine rosin-containing tooth varnish. Although colophony is a well-known cause of allergic contact dermatitis, it would not be expected to contain pine nut allergens, and there are no reports of immediate-type hypersensitivity reactions to rosin in patients with pine nut allergy.

SESAME SEED

Sesame oil

A number of medications contain sesame oil as an ingredient, and some list allergy to sesame oil as a contraindication. Food-grade sesame oil is typically used unrefined for its flavor,¹⁹⁴ and there are rare reports of patients with allergic reactions to sesame oil because of protein contamination.¹⁹⁵ However, refined pharmaceutical-grade sesame oil would not be expected to be allergenic unless it was contaminated by residual protein, and there are no reports of allergic reactions to sesame oil-containing medications.

SHELLFISH

Glucosamine

Glucosamine is an amino sugar derived from the shells of shellfish. Potentially allergic skin reactions have been reported in association with the ingestion of glucosamine.^{151,152} There is a single case report of an urticaria/angioedema reaction to the ingestion of glucosamine in a patient with no mention of shellfish allergy.¹⁵³ A skin prick test response was negative but intradermal test results were positive in the patient but negative in 10 control subjects, and an ELISA result was negative. Another report describes an asthma exacerbation after glucosamine ingestion, but there was no mention of shellfish allergy, and no testing was performed.¹⁵⁴ On the other hand, 6 patients with documented shellfish allergy by history and skin testing underwent glucosamine skin tests, results of all of which were negative, and oral challenges, all of which were uneventful.¹⁵⁵ Another study describes 15 patients with shrimp allergy who

consumed shrimp-derived glucosamine without a reaction.¹⁵⁶ Thus, shellfish-allergic patients need not avoid glucosamine.

Iodine

Both shellfish and radiocontrast media contain iodine, and both can cause anaphylactic reactions. However, anaphylactic reactions to shellfish are IgE mediated, with allergic antibodies directed against protein constituents, whereas anaphylactic reactions to radiocontrast media are not IgE mediated but rather related to osmolarity. Neither shellfish nor radiocontrast reactions are related to iodine directly, and there is no association between these 2 reactions. Although atopy in general might slightly increase the risk of reactions to radiocontrast media, shellfish allergy does not pose any particular risk.¹⁵⁷ Thus patients with shellfish allergy do not require special precautions when receiving radiocontrast media unless they have had a prior reaction to radiocontrast media itself.

SOY

Reports of allergic reactions to pharmaceuticals in patients with soy allergy are rare, and in general, such patients need not avoid the products below.

Soy lecithin

As described above, the term lecithin describes certain fatty substances derived for pharmaceutical use of soybean oil and egg yolk.¹⁸⁰ Soy lecithin can contain residual soy protein,¹⁵⁸⁻¹⁶⁰ although reports of allergic reactions are rare and largely unsubstantiated, and thus patients with soy allergy need not avoid soy lecithin.

Metered-dose inhalers. There are a few reports of asthma exacerbations or other potentially allergic reactions in association with the use of metered-dose inhalers containing soy lecithin.¹⁶¹⁻¹⁶⁶ In some of these reports, the authors have speculated that the reactions might have been due to soy allergy, although none of the reports describe any testing to investigate this possibility.

Soy oil

Intravenous lipid emulsions (ILEs). Most ILEs used for total parenteral nutrition (TPN) contain soy oil as a source of fat. There have been a small number of urticarial or anaphylactic reactions reported in association with the infusion of this material.¹⁶⁷⁻¹⁷² In some cases the reactions were reproducible,^{167,169} but in other cases they were not.^{169,170} In most cases skin tests to the suspect ILE were not performed, but when they were, the results were negative, suggesting the reactions were not IgE mediated.^{167,169,172} TPN regimens typically include, along with ILEs, solutions containing amino acids and vitamins. There are a number of reports of urticarial or anaphylactic reactions to TPN regimens that either did not include ILEs^{196,197} or in which the ILE component was tolerated but some other component appeared to be responsible for the reaction.¹⁹⁸⁻²⁰⁰ Some samples of soybean oil have been demonstrated to contain very low but measurable quantities of soy proteins,^{158,159} but immunoblotting with sera from patients with soy allergy did not show any IgE binding.¹⁵⁹ Thus although it is clear that TPN with or without ILEs can rarely cause anaphylactic reactions, the mechanism of these reactions is unclear and appears unrelated to soy allergy.

Soy phosphatidylcholine

Liposomal amphotericin B. Amphotericin B is available in a liposomal preparation in which the principal constituent of the liposome is soy phosphatidylcholine. Anaphylactic reactions to the infusion of this preparation have been reported,²⁰¹⁻²⁰⁹ including 1 death.²⁰⁶ Some of these patients tolerated the subsequent infusion of a nonliposomal preparation of amphotericin, strongly suggesting that something other than the drug itself was the cause.^{201,207,208} None of the reports mention soy allergy in the patients or as a speculated mechanism.

SUMMARY

Certain substances derived from foodstuffs are used as excipients in drugs and vaccines for their pharmaceutical properties. Some of these food-derived excipients contain food proteins either intentionally or unintentionally as contaminants. As such, patients who have IgE antibodies directed against these food proteins are theoretically at risk for allergic reactions when exposed to the food proteins in the medications. However, such reactions are quite rare, usually because the amount of food protein is not present in a large enough quantity to elicit a reaction or because the particular protein is not a common allergen. When the food protein appears as an unintentional contaminant, the amount of protein, if any, that is present might be variable and might elicit reactions only from some lots of medication that happen to contain more of the food protein or illicit reactions only in patients who are exquisitely sensitive or happen to have IgE antibodies directed against a particular epitope in the contaminating protein. In most circumstances these medications should not be routinely withheld from patients who have particular food allergies because the overwhelming majority will tolerate the medications uneventfully. However, if a particular patient has had an apparent allergic reaction to the medication, allergy to the food component should be investigated as a possible cause. Even in this circumstance (ie, an allergic reaction to a medication in a patient allergic to a particular food and the presence of the food protein in the medication), the food protein would still have to be demonstrated to be causal by using appropriate testing because other allergens present in the medication could have been the cause or the medication might be capable of non-IgE-mediated mast cell degranulation.

REFERENCES

- Haywood A, Glass BD. Pharmaceutical excipients—where do we begin? *Australian Prescriber* 2011;34:112-4.
- Audicana Berasategui MT, Barasona Villarejo MJ, Corominas Sanchez M, De Barrio Fernandez M, Garcia Aviles MC, Garcia Robaina JC, et al. Potential hypersensitivity due to the food or food additive content of medicinal products in Spain. *J Investig Allergol Clin Immunol* 2011;21:496-506.
- Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. *J Allergy Clin Immunol* 2012;130:25-43.
- Kamin PB, Fein BT, Britton HA. Live, attenuated measles vaccine: its administration to children allergic to egg protein. *JAMA* 1963;185:647-50.
- Kamin PB, Fein BT, Britton HA. Use of live, attenuated measles virus vaccine in children allergic to egg protein. *JAMA* 1965;193:1125-6.
- Brown FR, Wolfe HI. Chick embryo grown measles vaccine in an egg-sensitive child. *J Pediatr* 1967;71:868-9.
- Cohen HI. Safety of measles vaccine in egg-sensitive individuals. *J Pediatr* 1978;92:859.
- Katz SL. Safety of measles vaccine in egg-sensitive individuals. *J Pediatr* 1978;92:859.

9. Aukrust L, Almeland TL, Refsum D, Aas K. Severe hypersensitivity or intolerance reactions to measles vaccine in six children. Clinical and immunological studies. *Allergy* 1980;35:581-7.
10. Nieburg PI, Preblud SR, Halsey NA, Brandling-Bennett AD, Hinman AR. Measles vaccine in egg-allergic children. *Pediatrics* 1980;65:365-6.
11. Herman JJ, Radin R, Schneiderman R. Allergic reactions to measles (rubeola) vaccine in patients hypersensitive to egg protein. *J Pediatr* 1983;102:196-9.
12. Greenberg MA, Bix DL. Safe administration of mumps-measles-rubella vaccine in egg-allergic children. *J Pediatr* 1988;113:504-6.
13. Peter G. Administration of measles-mumps-rubella vaccine to children allergic to eggs. *J Pediatr* 1989;114:1067.
14. Kemp A, Van Asperen P, Mukhi A. Measles immunization in children with clinical reactions to egg protein. *Am J Dis Child* 1990;144:33-5.
15. Stiehm ER. Skin testing prior to measles vaccination for egg-sensitive patients. *Am J Dis Child* 1990;144:32.
16. Kletz MR, Holland CL, Mendelson JS, Bielory L. Administration of egg-derived vaccines in patients with history of egg sensitivity. *Ann Allergy* 1990;64:527-9.
17. Kornbrot B, Levy Y, Garty BZ, Danon YL. Allergic reactions to measles, mumps and rubella vaccine in children with egg protein allergy. *Harefuah* 1990;119:230-1.
18. Lavi S, Zimmerman B, Koren G, Gold R. Administration of measles, mumps, and rubella virus vaccine (live) to egg-allergic children. *JAMA* 1990;263:269-71.
19. Bruno G, Giampietro PG, Grandolfo ME, Milita O, Businco L. Safety of measles immunisation in children with IgE-mediated egg allergy. *Lancet* 1990;335:739.
20. Beck S, Williams L, Shirrell M, Burks A. Egg hypersensitivity and measles-mumps-rubella vaccine administration. *Pediatrics* 1991;88:913-7.
21. Businco L, Grandolfo M, Bruno G. Safety of measles immunization in egg-allergic children. *Pediatr Allergy Immunol* 1991;4:195-8.
22. Fasano MB, Wood RA, Cooke SK, Sampson HA. Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine. *J Pediatr* 1992;120:878-81.
23. Horner AA, Schneider LC, Broff MD. Incidence of positive skin tests with the measles-mumps-rubella (MMR) vaccine in egg allergic children and non-allergic adults. *J Allergy Clin Immunol* 1992;89:350.
24. Puvvada L, Silverman B, Bassett C, Chiamonte LT. Systemic reactions to measles-mumps-rubella vaccine skin testing. *Pediatrics* 1993;91:835-6.
25. Tounian P, Delacourt C, de Blic J, Paupe J, Scheinmann P. Vaccinations of children allergic to eggs with vaccine prepared with egg. *Arch Fr Pediatr* 1993;50:191-5.
26. Trotter AC, Stone BD, Laszlo DJ, Georgitis JW. Measles, mumps, rubella vaccine administration in egg-sensitive children: systemic reactions during vaccine desensitization. *Ann Allergy* 1994;72:25-8.
27. Aickin R, Hill D, Kemp A. Measles immunisation in children with allergy to egg. *BMJ* 1994;309:223-5.
28. Businco L. Measles, mumps, rubella immunization in egg-allergic children: a long-lasting debate. *Ann Allergy* 1994;72:1-3.
29. Freigang B, Jadavji TP, Freigang DW. Lack of adverse reactions to measles, mumps, and rubella vaccine in egg-allergic children. *Ann Allergy* 1994;73:486-8.
30. James JM, Burks AW, Roberson PK, Sampson HA. Safe administration of the measles vaccine to children allergic to eggs. *N Engl J Med* 1995;332:1262-6.
31. Des Roches A, Paradis L, Gagnon R, Lemire C, Begin P, Carr S, et al. Egg-allergic patients can be safely vaccinated against influenza. *J Allergy Clin Immunol* 2012;130:1213-6.e1.
32. Bierman CW, Shapiro GG, Pierson WE, Taylor JW, Foy HM, Fox JP. Safety of influenza vaccination in allergic children. *J Infect Dis* 1977;136(Suppl):S652-5.
33. James JM, Zeiger RS, Lester MR, Fasano MB, Gern JE, Mansfield LE, et al. Safe administration of influenza vaccine to patients with egg allergy. *J Pediatr* 1998;133:624-8.
34. Zeiger RS. Current issues with influenza vaccination in egg allergy. *J Allergy Clin Immunol* 2002;110:834-40.
35. Dorsey MJ, Song L, Geha T, Timmons A, Oettgen H, Schneider L. Influenza vaccine in 55 patients with egg allergy. *J Allergy Clin Immunol* 2005;115(Suppl):S250.
36. Esposito S, Gasparini C, Martelli A, Zenga A, Tremolati E, Varin E, et al. Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. *Vaccine* 2008;26:4664-8.
37. Hotte SL, Lejtenyi C, Primeau M. A 6-year experience with influenza vaccination in egg allergic patients. *J Allergy Clin Immunol* 2008;121(Suppl):S239.
38. Park AY, Pien GC, Stinson R, Brown-Whitehorn TF, Spergel JM. Administration of influenza vaccine to patients with egg allergy. *J Allergy Clin Immunol* 2008;121(Suppl):S240.
39. Saltzman RW, Park AY, Pien GC, Stinson R, Spergel JM. Administration of influenza vaccine to pediatric patients with egg allergy. *J Allergy Clin Immunol* 2009;123(Suppl):S175.
40. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. *Pediatrics* 2010;125:e1024-30.
41. Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, et al. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. *J Allergy Clin Immunol* 2010;126:317-23.
42. Greenhawt MJ, Chernin AS, Howe L, Li JT, Sanders G. The safety of the H1N1 influenza A vaccine in egg allergic individuals. *Ann Allergy Asthma Immunol* 2010;105:387-93.
43. Leo S, Dean J, Chan E. Safety of H1N1 and seasonal influenza vaccines in egg allergic patients in British Columbia. *Allergy Asthma Clin Immunol* 2010;6:P4.
44. Pien GC, LeBenger KS, Carotenuto DR, Difilippi M, Scarpino D, Simmons JM, et al. Coordination of multidisciplinary resources for vaccination of egg-allergic individuals during an H1N1 (novel) influenza pandemic. *Allergy Asthma Proc* 2010;31:507-10.
45. Thanik ES, Cox AL, Sampson HA. Administration of a low egg-containing influenza vaccine [Fluarix®] in an egg-allergic pediatric population [abstract]. *J Allergy Clin Immunol* 2010;125:AB25.
46. Siret-Alatrista A, Bouali F, Demoly M, Bousquet PJ, Demoly P. The 2009-2010 H1N1 vaccination campaign for patients with egg allergy in a region of France. *Allergy* 2011;66:298-9.
47. Boden SR, LaBelle VS, Sedlak DA, Kim EH, Vickery BP, Burks AW. Safe administration of flu vaccine in egg allergic patients [abstract]. *J Allergy Clin Immunol* 2011;127:AB114.
48. Paschall VL, Siles RI, Bhatti H, Nolder PJ, Melton AL. Do egg-specific IgE levels predict reactions to seasonal influenza or H1N1 vaccination? [abstract]. *J Allergy Clin Immunol* 2011;127:AB182.
49. Owens G, Macginnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. *J Allergy Clin Immunol* 2011;127:264-5.
50. Howe LE, Conlon AS, Greenhawt MJ, Sanders GM. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. *Ann Allergy Asthma Immunol* 2011;106:446-7.
51. Webb L, Petersen M, Boden S, Labelle V, Bird JA, Howell D, et al. Single-dose influenza vaccination of patients with egg allergy in a multicenter study. *J Allergy Clin Immunol* 2011;128:218-9.
52. Pitt T, Kalicinsky C, Warrington R, Cisneros N. Assessment of epicutaneous testing of a monovalent Influenza A (H1N1) 2009 vaccine in egg allergic patients. *Allergy Asthma Clin Immunol* 2011;7:3.
53. Schuler JE, King WJ, Dayneka NL, Rastelli L, Marquis E, Chad Z, et al. Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease. *Can J Public Health* 2011;102:196-9.
54. Forsdahl BA. Reactions of Norwegian children with severe egg allergy to an egg-containing influenza A (H1N1) vaccine: a retrospective audit. *BMJ Open* 2012;2:e000186.
55. Fung I, Spergel JM. Administration of influenza vaccine to pediatric patients with egg-induced anaphylaxis. *J Allergy Clin Immunol* 2012;129:1157-9.
56. Khan FS, Virant FS, Furukawa CT, Altman LC, Williams PV, Kennedy MS, et al. Influenza vaccine administration in egg allergic children [abstract]. *J Allergy Clin Immunology* 2012;129:AB70.
57. Upton J, Hummel D, Kasprzak A, Atkinson A. No systemic reactions to influenza vaccination in egg-sensitized tertiary-care pediatric patients. *Allergy Asthma Clin Immunol* 2012;8:2.
58. Greenhawt MJ, Spergel JM, Rank MA, Green TD, Masnoor D, Sharma H, et al. Safe administration of the seasonal trivalent influenza vaccine to children with severe egg allergy. *Ann Allergy Asthma Immunol* 2012;109:426-30.
59. Waibel KH, Gomez R. Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines. *J Allergy Clin Immunol* 2010;125:749-51.e1.
60. Li JT, Rank MA, Squillace DL, Kita H. Ovalbumin content of influenza vaccines. *J Allergy Clin Immunol* 2010;125:1412-3.
61. McKinney KK, Webb L, Petersen M, Nelson M, Laubach S. Ovalbumin content of 2010-2011 influenza vaccines. *J Allergy Clin Immunol* 2011;127:1629-32.
62. Intralipid [package insert] Deerfield, IL. Baxter. 2006.
63. Lunn M, Fausnight T. Hypersensitivity to total parenteral nutrition fat-emulsion component in an egg-allergic child. *Pediatrics* 2011;128:e1025-8.
64. Briggs LP, Clarke RS, Watkins J. An adverse reaction to the administration of disoprofol (Diprivan). *Anaesthesia* 1982;37:1099-101.
65. Aitken HA. Weals after propofol. *Anaesthesia* 1988;43:170.
66. Laxenaire MC, Gueant JL, Bermejo E, Mouton C, Navez MT. Anaphylactic shock due to propofol. *Lancet* 1988;2:739-40.
67. Dold M, Konarszewski WH. Delayed allergic response to propofol. *Anaesthesia* 1989;44:533.
68. Kumar CM, McNeela BJ. Ocular manifestation of propofol allergy. *Anaesthesia* 1989;44:266.
69. Naquib M. Anaphylactoid reactions following propofol-atracurium sequence. *Can J Anaesth* 1989;36:358-9.

70. de Leon-Casasola OA, Weiss A, Lema MJ. Anaphylaxis due to propofol. *Anesthesiology* 1992;77:384-6.
71. Laxenaire MC, Mata-Bermejo E, Moneret-Vautrin DA, Gueant JL. Life-threatening anaphylactoid reactions to propofol (Diprivan). *Anesthesiology* 1992;77:275-80.
72. McHale SP, Konieczko K. Anaphylactoid reaction to propofol. *Anaesthesia* 1992;47:864-5.
73. Bassett CW, Talusan-Canlas E, Holtzin L, Kumar S, Chiamonte LT. Case report: an adverse reaction to propofol in a patient with egg hypersensitivity. *J Allergy Clin Immunol* 1994;93:242.
74. Ducart AR, Watremez C, Louagie YA, Collard EL, Broka SM, Joucken KL. Propofol-induced anaphylactoid reaction during anesthesia for cardiac surgery. *J Cardiothorac Vasc Anesth* 2000;14:200-1.
75. Nishiyama T, Hanaoka K. Propofol-induced bronchoconstriction: two case reports. *Anesth Analg* 2001;93:645-6.
76. Tsai MH, Kuo PH, Hong RL, Yang PC. Anaphylaxis after propofol infusion for Port-A-Cath insertion in a 35-year old man. *J Formos Med Assoc* 2001;100:424-6.
77. Hofer KN, McCarthy MW, Buck ML, Hendrick AE. Possible anaphylaxis after propofol in a child with food allergy. *Ann Pharmacother* 2003;37:398-401.
78. Shin CH, Lee YH, Kim YM, Park SH, Sung IY, Choi SW, et al. Severe oropharyngeal angioedema caused by propofol: a case report. *Korean J Anesthesiol* 2006;50(Suppl):S68-70.
79. Chung IK, Jeon SW, Kim SU, Sohn JW, Jung DW, Jung MK, et al. A case of propofol-induced anaphylaxis. *Korean J Med* 2010;79:549-52.
80. You BC, Jang AS, Han JS, Cheon HW, Park JS, Lee JH, et al. A case of propofol-induced oropharyngeal angioedema and bronchospasm. *Allergy Asthma Immunol Res* 2012;4:46-8.
81. Murphy A, Campbell DE, Baines D, Mehr S. Allergic reactions to propofol in egg-allergic children. *Anesth Analg* 2011;113:140-4.
82. Doshi AB, Moshfeghi DM, Jack RL. Anaphylactoid reaction after verteporfin therapy. *Am J Ophthalmol* 2005;140:936-7.
83. Caplan SN, Berkman EM. Letter: protamine sulfate and fish allergy. *N Engl J Med* 1976;295:172.
84. Knape JT, Schuller JL, de Haan P, de Jong AP, Bovill JG. An anaphylactic reaction to protamine in a patient allergic to fish. *Anesthesiology* 1981;55:324-5.
85. Levy JH, Schwieger IM, Zaidan JR, Faraj BA, Weintraub WS. Evaluation of patients at risk for protamine reactions. *J Thorac Cardiovasc Surg* 1989;98:200-4.
86. Weiss ME, Nyhan D, Peng ZK, Horrow JC, Lowenstein E, Hirshman C, et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. *N Engl J Med* 1989;320:886-92.
87. Weiler JM, Gellhaus MA, Carter JG, Meng RL, Benson PM, Hottel RA, et al. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. *J Allergy Clin Immunol* 1990;85:713-9.
88. Kimmel SE, Sekeres MA, Berlin JA, Ellison N, DiSesa VJ, Strom BL. Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass. *J Am Coll Cardiol* 1998;32:1916-22.
89. Bollinger ME, Hamilton RG, Wood RA. Protamine allergy as a complication of insulin hypersensitivity: a case report. *J Allergy Clin Immunol* 1999;104:462-5.
90. Hakala T, Suojäranta-Ylinen R. Fatal anaphylactic reaction to protamine after femoropopliteal by-pass surgery. *Ann Chir Gynaecol* 2000;89:150-2.
91. Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. *Basic Clin Pharmacol Toxicol* 2008;103:192-6.
92. Greenberger PA, Patterson R, Tobin MC, Liotta JL, Roberts M. Lack of cross-reactivity between IgE to salmon and protamine sulfate. *Am J Med Sci* 1989;298:104-8.
93. Horrow JC, Pharo GH, Levit LS, Freeland C. Neither skin tests nor serum enzyme-linked immunosorbent assay tests provide specificity for protamine allergy. *Anesth Analg* 1996;82:386-9.
94. Mark BJ, Beaty AD, Slavin RG. Are fish oil supplements safe in finned fish-allergic patients? *Allergy Asthma Proc* 2008;29:528-9.
95. Sakaguchi M, Nakayama T, Inouye S. Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines. *J Allergy Clin Immunol* 1996;98:1058-61.
96. Kelso JM, Jones RT, Yunginger JW. Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin. *J Allergy Clin Immunol* 1993;91:867-72.
97. Haeney MR. Angio-edema and urticaria associated with omeprazole. *BMJ* 1992;305:10.
98. Land MH, Piehl MD, Burks AW. Near fatal anaphylaxis from orally administered gelatin capsule. *J Allergy Clin Immunol Pract* 2013;1:99-100.
99. Sakaguchi M, Inouye S. Anaphylaxis to gelatin-containing rectal suppositories. *J Allergy Clin Immunol* 2001;108:1033-4.
100. Sakaguchi M, Kaneda H, Inouye S. A case of anaphylaxis to gelatin included in erythropoietin products. *J Allergy Clin Immunol* 1999;103:349-50.
101. Khoriaty E, McClain CD, Permaul P, Smith ER, Rachid R. Intraoperative anaphylaxis induced by the gelatin component of thrombin-soaked Gelfoam in a pediatric patient. *Ann Allergy Asthma Immunol* 2012;108:209-10.
102. Spencer HT, Hsu JT, McDonald DR, Karlin LI. Intraoperative anaphylaxis to gelatin in topical hemostatic agents during anterior spinal fusion: a case report. *Spine J* 2012;22:e1-6.
103. Lund N. Anaphylactic reaction induced by infusion of Haemacel. *Br J Anaesth* 1973;45:929.
104. Wisborg K. Letter: anaphylactic reactions induced by infusion of polygeline (haemacel). *Br J Anaesth* 1975;47:1116-7.
105. Lorenz W, Doenicke A, Messmer K, Reimann HJ, Thermann M, Lahn W, et al. Histamine release in human subjects by modified gelatin (Haemacel) and dextran: an explanation for anaphylactoid reactions observed under clinical conditions? *Br J Anaesth* 1976;48:151-65.
106. Lorenz W, Doenicke A, Dittmann I, Hug P, Schwarz B. [Anaphylactoid reactions following administration of plasma substitutes in man. Prevention of this side-effect of haemacel by premedication with H1- and H2-receptor antagonists (author's translation)]. *Anaesthesist* 1977;26:644-8.
107. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. *Lancet* 1977;1:466-9.
108. Freeman MK. Fatal reaction to haemacel. *Anaesthesia* 1979;34:341-3.
109. Lorenz W, Doenicke A, Schoning B, Mamorski J, Weber D, Hinterlang E, et al. H1 + H2-receptor antagonists for premedication in anaesthesia and surgery: a critical view based on randomized clinical trials with Haemacel and various anti-allergic drugs. *Agents Actions* 1980;10:114-24.
110. Lundsgaard-Hansen P, Tschirren B. Clinical experience with 120,000 units of modified fluid gelatin. *Dev Biol Stand* 1980;48:251-6.
111. Schoning B, Lorenz W. Prevention of allergoid (cutaneous anaphylactoid) reactions to polygeline (Haemacel) in orthopaedic patients by premedication with H1- and H2-receptor antagonists. *Dev Biol Stand* 1980;48:241-9.
112. Vervloet D, Senft M, Dugue P, Arnaud A, Charpin J. Anaphylactic reactions to modified fluid gelatins. *J Allergy Clin Immunol* 1983;71:535-40.
113. Duffy BL, Harding JN, Fuller WR, Peake SL. Cardiac arrest following Haemacel. *Anaesth Intensive Care* 1994;22:90-2.
114. Chew GY, Phan TG, Quin JW. Anaphylactic or anaphylactoid reaction to Haemacel? *Med J Aust* 1999;171:387-8.
115. Ford SA, Kam PC, Baldo BA, Fisher MM. Anaphylactic or anaphylactoid reactions in patients undergoing cardiac surgery. *J Cardiothorac Vasc Anesth* 2001;15:684-8.
116. Jenkins SC, Clifton MA. Gelofusine allergy—the need for identification jewelry. *Ann R Coll Surg Engl* 2002;84:206-7.
117. Russell WJ, Fenwick DG. Anaphylaxis to Haemacel and cross reactivity to Gelofusin. *Anaesth Intensive Care* 2002;30:481-3.
118. Apostolou E, Deckert K, Puy R, Sandrini A, de Leon MP, Douglass JA, et al. Anaphylaxis to Gelofusine confirmed by in vitro basophil activation test: a case series. *Anaesthesia* 2006;61:264-8.
119. Marrel J, Christ D, Spahn DR. Anaphylactic shock after sensitization to gelatin. *Br J Anaesth* 2011;107:647-8.
120. Ring J. Anaphylactoid reactions to plasma substitutes. *Int Anesthesiol Clin* 1985;23:67-95.
121. Block MB, Thompson JS, Polcyn RE. Anaphylactoid reaction to technetium-99m sulfur colloid stabilized with gelatin. Report of a case. *Am J Dig Dis* 1970;15:569-71.
122. Sakaguchi M, Ogura H, Inouye S. IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines. *J Allergy Clin Immunol* 1995;96:563-5.
123. Kumagai T, Yamanaka T, Wataya Y, Umetsu A, Kawamura N, Ikeda K, et al. Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. *J Allergy Clin Immunol* 1997;100:130-4.
124. Sakaguchi M, Yamanaka T, Ikeda K, Sano Y, Fujita H, Miura T, et al. IgE-mediated systemic reactions to gelatin included in the varicella vaccine. *J Allergy Clin Immunol* 1997;99:263-4.
125. Sakaguchi M, Yoshida M, Kuroda W, Harayama O, Matsunaga Y, Inouye S. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. *Vaccine* 1997;15:121-2.
126. Sakaguchi M, Yoshida T, Asahi T, Aoki T, Miyatani Y, Inouye S. Development of IgE antibody to gelatin in children with systemic immediate-type reactions to vaccines. *J Allergy Clin Immunol* 1997;99:720-1.
127. Sakaguchi M, Inouye S. Two patterns of systemic immediate-type reactions to Japanese encephalitis vaccines. *Vaccine* 1998;16:68-9.
128. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of

- gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. *J Allergy Clin Immunol* 1999;103:321-5.
129. Singer S, Johnson CE, Mohr R, Holowecky C. Urticaria following varicella vaccine associated with gelatin allergy. *Vaccine* 1999;17:327-9.
130. Sakaguchi M, Inouye S. Systemic allergic reactions to gelatin included in vaccines as a stabilizer. *Jpn J Infect Dis* 2000;53:189-95.
131. Worm M, Sterry W, Zuberbier T. Gelatin-induced urticaria and anaphylaxis after tick-borne encephalitis vaccine. *Acta Derm Venereol* 2000;80:232.
132. Patja A, Makinen-Kiljunen S, Davidkin I, Paunio M, Peltola H. Allergic reactions to measles-mumps-rubella vaccination. *Pediatrics* 2001;107:E27.
133. Sakaguchi M, Miyazawa H, Inouye S. Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines. *Allergy* 2001;56:536-9.
134. Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. *Pediatrics* 2002;110:e71.
135. Lasley MV. Anaphylaxis after booster influenza vaccine due to gelatin allergy. *Pediatr Asthma Allergy Immunol* 2007;20:201-5.
136. Sakaguchi M, Nakayama T, Fujita H, Toda M, Inouye S. Minimum estimated incidence in Japan of anaphylaxis to live virus vaccines including gelatin. *Vaccine* 2000;19:431-6.
137. Kuno-Sakai H, Kimura M. Removal of gelatin from live vaccines and DTaP-an ultimate solution for vaccine-related gelatin allergy. *Biologicals* 2003;31:245-9.
138. Ozaki T, Nishimura N, Muto T, Sugata K, Kawabe S, Goto K, et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. *Vaccine* 2005;23:1208.
139. Nakayama T, Aizawa C. Change in gelatin content of vaccines associated with reduction in reports of allergic reactions. *J Allergy Clin Immunol* 2000;106:591-2.
140. Kattan JD, Konstantinou GN, Cox AL, Nowak-Węgrzyn A, Gimenez G, Sampson HA, et al. Anaphylaxis to diphtheria, tetanus, and pertussis vaccines among children with cow's milk allergy. *J Allergy Clin Immunol* 2011;128:215-8.
141. Slater JE, Rabin RL, Martin D. Comments on cow's milk allergy and diphtheria, tetanus, and pertussis vaccines. *J Allergy Clin Immunol* 2011;128:434.
142. Martin-Munoz MF, Fortuni M, Caminoa M, Belver T, Quirce S, Caballero T. Anaphylactic reaction to probiotics. Cow's milk and hen's egg allergens in probiotic compounds. *Pediatr Allergy Immunol* 2012;23:778-84.
143. Parisi CA, Smailini PL, Gervasoni ME, Maspero JF, Docena GH. Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy. *Clin Exp Allergy* 2013;43:249-54.
144. Fiocchi A, Restani P, Leo G, Martelli A, Bouygue GR, Terracciano L, et al. Clinical tolerance to lactose in children with cow's milk allergy. *Pediatrics* 2003;112:359-62.
145. Eda A, Sugai K, Shioya H, Fujitsuka A, Ito S, Iwata T, et al. Acute allergic reaction due to milk proteins contaminating lactose added to corticosteroid for injection. *Allergol Int* 2009;58:137-9.
146. Nowak-Węgrzyn A, Shapiro GG, Beyer K, Bardina L, Sampson HA. Contamination of dry powder inhalers for asthma with milk proteins containing lactose. *J Allergy Clin Immunol* 2004;113:558-60.
147. Sa AB, Oliveira LCL, Miyagi KVM, Mello YAMF, Cabral EC, Carvalho APE, et al. Reaction due to milk proteins contaminating lactose added to inhaled corticosteroid [abstract]. *J Allergy Clin Immunol* 2011;127:AB241.
148. Morisset M, Moneret-Vautrin D, Commun N, Schuller A, Kanny G. Allergy to cow milk proteins contaminating lactose, common excipient of dry powder inhalers for asthma. *J Allergy Clin Immunol* 2006;117(Suppl):S95.
149. Maiello N, Del Giudice MM, Capristo C, Decimo F, Santaniello F, Perrone L, et al. Severe allergic reaction to lactulose in a child with milk allergy. *Ann Allergy Asthma Immunol* 2011;107:85.
150. Preventech Vella® sodium fluoride varnish Available at: <http://www.preventech.com/vella.html>. Accessed April 9, 2014.
151. Skin reactions with glucosamine. *Aust Adv Drug React Bull* 2005;24:23.
152. Glucosamine allergy. *Prescrire Int* 2006;15:139.
153. Matheu V, Gracia Bara MT, Pelta R, Vivas E, Rubio M. Immediate-hypersensitivity reaction to glucosamine sulfate. *Allergy* 1999;54:643.
154. Tallia AF, Cardone DA. Asthma exacerbation associated with glucosamine-chondroitin supplement. *J Am Board Fam Pract* 2002;15:481-4.
155. Gray HC, Hutcheson PS, Slavin RG. Is glucosamine safe in patients with seafood allergy? *J Allergy Clin Immunol* 2004;114:459-60.
156. Villacis J, Rice TR, Bucci LR, El-Dahr JM, Wild L, Demerell D, et al. Do shrimp-allergic individuals tolerate shrimp-derived glucosamine? *Clin Exp Allergy* 2006;36:1457-61.
157. Schabelman E, Witting M. The relationship of radiocontrast, iodine, and seafood allergies: a medical myth exposed. *J Emerg Med* 2010;39:701-7.
158. Porras O, Carlsson B, Fallstrom SP, Hanson LA. Detection of soy protein in soy lecithin, margarine and, occasionally, soy oil. *Int Arch Allergy Appl Immunol* 1985;78:30-2.
159. Awazuhara H, Kawai H, Baba M, Matsui T, Komiyama A. Antigenicity of the proteins in soy lecithin and soy oil in soybean allergy. *Clin Exp Allergy* 1998;28:1559-64.
160. Gu X, Beardslee T, Zeece M, Sarath G, Markwell J. Identification of IgE-binding proteins in soy lecithin. *Int Arch Allergy Immunol* 2001;126:218-25.
161. Connolly CK. Adverse reaction to ipratropium bromide. *Br Med J (Clin Res Ed)* 1982;285:934-5.
162. Fine SR. Possible reactions to soya lecithin in aerosols. *J Allergy Clin Immunol* 1991;87:600.
163. Bone WD, Amundson DE. An unusual case of severe anaphylaxis due to ipratropium bromide inhalation. *Chest* 1993;103:981-2.
164. Facchini G, Antonicelli L, Cinti B, Bonifazi F, Massei V. Paradoxical bronchospasm and cutaneous rash after metered-dose inhaled bronchodilators. *Monaldi Arch Chest Dis* 1996;51:201-3.
165. Karch AM, Karch FE. It was a shock. *Am J Nurs* 2003;103:27.
166. Beliveau S, Gaudreault P, Goulet L, Primeau MN, Marcoux D. Type I hypersensitivity in an asthmatic child allergic to peanuts: was soy lecithin to blame? *J Cutan Med Surg* 2008;12:27-30.
167. Kamath KR, Berry A, Cummins G. Acute hypersensitivity reaction to Intralipid. *N Engl J Med* 1981;304:360.
168. Hiyama DT, Griggs B, Mittman RJ, Lacy JA, Benson DW, Bower RH. Hypersensitivity following lipid emulsion infusion in an adult patient. *J Parenter Enteral Nutr* 1989;13:318-20.
169. Buchman AL, Ament ME. Comparative hypersensitivity in intravenous lipid emulsions. *J Parenter Enteral Nutr* 1991;15:345-6.
170. Weidmann B, Lepique C, Heider A, Schmitz A, Niederle N. Hypersensitivity reactions to parenteral lipid solutions. *Support Care Cancer* 1997;5:504-5.
171. Market AD, Lew DB, Schropp KP, Hak EB. Parenteral nutrition-associated anaphylaxis in a 4-year-old child. *J Pediatr Gastroenterol Nutr* 1998;26:229-31.
172. Babakissa C, Lemire C, Beaulieu G, Ferretti E. Hypersensitivity reaction to parenteral nutrition in an intrauterine growth-restricted newborn: a case report. *J Parenter Enteral Nutr* 2011;35:402-4.
173. Red Book—Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village (IL): American Academy of Pediatrics; 2012.
174. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices—United States, 2013-2014. *MMWR Morb Mortal Wkly Rep* 2013;62:1-43.
175. Recommendations for prevention and control of influenza in children, 2013-2014. *Pediatrics* 2013;132:e1089-104.
176. FLUCELVAX [package insert]. Emeryville (CA): Novartis; 2012.
177. FLUBLOK Meriden, CT (Protein Sciences) [package insert]. 2013.
178. Recommendations for Prevention and Control of Influenza in Children, 2013-2014. *Pediatrics* 2013.
179. YF-VAX [package insert]. Lyon (France): Sanofi Pasteur; 2010.
180. Martin-Hernandez C, Benet S, Marvin-Guy LF. Characterization and quantification of proteins in lecithins. *J Agric Food Chem* 2005;53:8607-13.
181. DIPRIVAN—propofol injection, emulsion [package insert]. London (United Kingdom): AstraZeneca Pharmaceuticals; 2005.
182. DIPRIVAN—propofol injection, emulsion [package insert]. APP Pharmaceuticals. Schaumburg, IL. 2009.
183. Balhorn R. The protamine family of sperm nuclear proteins. *Genome Biol* 2007;8:227.
184. Disease management of drug hypersensitivity: a practice parameter. *Ann Allergy Asthma Immunol* 1999;83:665-700.
185. Health Canada's Position on Highly Refined Oils Derived from Food Allergen Sources. Bureau of Chemical Safety, Food Directorate, Health Products and Food Branch; 2013. Available at: http://www.hc-sc.gc.ca/fn-an/alt_formats/pdf/label-etiquet/allergen/oil-refined-huile-raffinees-eng.pdf. Accessed April 9, 2014.
186. Sakaguchi M, Hori H, Ebihara T, Irie S, Yanagida M, Inouye S. Reactivity of the immunoglobulin E in bovine gelatin-sensitive children to gelatins from various animals. *Immunology* 1999;96:286-90.
187. Bogdanovic J, Halsey NA, Wood RA, Hamilton RG. Bovine and porcine gelatin sensitivity in children sensitized to milk and meat. *J Allergy Clin Immunol* 2009;124:1108-10.
188. Gelfoam [package insert]. Pfizer. New York, NY 2012.
189. Saddler JM, Horsey PJ. The new generation gelatins. A review of their history, manufacture and properties. *Anaesthesia* 1987;42:998-1004.
190. Sakaguchi M, Hori H, Hattori S, Irie S, Imai A, Yanagida M, et al. IgE reactivity to alpha1 and alpha2 chains of bovine type 1 collagen in children with bovine gelatin allergy. *J Allergy Clin Immunol* 1999;104:695-9.
191. Hori H, Hattori S, Inouye S, Kimura A, Irie S, Miyazawa H, et al. Analysis of the major epitope of the alpha2 chain of bovine type I collagen in children with bovine gelatin allergy. *J Allergy Clin Immunol* 2002;110:652-7.

192. Kumagai T, Yamanaka T, Wataya Y, Saito A, Okui T, Yano S, et al. A strong association between HLA-DR9 and gelatin allergy in the Japanese population. *Vaccine* 2001;19:3273-6.
193. Taylor SL, Busse WW, Sachs MI, Parker JL, Yunginger JW. Peanut oil is not allergenic to peanut-sensitive individuals. *J Allergy Clin Immunol* 1981;68:372-5.
194. Crevel RW, Kerkhoff MA, Koning MM. Allergenicity of refined vegetable oils. *Food Chem Toxicol* 2000;38:385-93.
195. Kanny G, De Hauteclouque C, Moneret-Vautrin DA. Sesame seed and sesame seed oil contain masked allergens of growing importance. *Allergy* 1996;51:952-7.
196. Pomeranz S, Gimmon Z, Ben Zvi A, Katz S. Parenteral Nutrition-Induced Anaphylaxis. *JPEN J Parenter Enteral Nutr* 1987;11:314-5.
197. Levy M, Dupuis L. Parenteral nutrition hypersensitivity. *JPEN J Parenter Enteral Nutr* 1990;14:213-5.
198. Bullock L, Etchason E, Fitzgerald J, McGuire W. Case report of an allergic reaction to parenteral nutrition in a pediatric patient. *JPEN J Parenter Enteral Nutr* 1990;14:98-100.
199. Huston RK, Baxter LM, Larrabee PB. Neonatal parenteral nutrition hypersensitivity: a case report implicating bisulfite sensitivity in a newborn infant. *JPEN J Parenter Enteral Nutr* 2009;33:691-3.
200. Bartels CL, Sanz C, Stec R, Coulter DW. Parenteral nutrition-induced hypersensitivity in an adolescent. *JPEN J Parenter Enteral Nutr* 2012;36:117-21.
201. Laing RB, Milne LJ, Leen CL, Malcolm GP, Steers AJ. Anaphylactic reactions to liposomal amphotericin. *Lancet* 1994;344:682.
202. Ringden O, Andstrom E, Remberger M, Svahn BM, Tollemar J. Allergic reactions and other rare side-effects of liposomal amphotericin. *Lancet* 1994;344:1156-7.
203. Bates CM, Carey PB, Hind CR. Anaphylaxis due to liposomal amphotericin (AmBisome). *Genitourin Med* 1995;71:414.
204. Torre I, Lopez-Herce J, Vazquez P. Anaphylactic reaction to liposomal amphotericin B in children. *Ann Pharmacother* 1996;30:1036-7.
205. Kauffman CA, Wiseman SW. Anaphylaxis upon switching lipid-containing amphotericin B formulations. *Clin Infect Dis* 1998;26:1237-8.
206. Schneider P, Klein RM, Dietze L, Sohngen D, Leschke M, Heyll A. Anaphylactic reaction to liposomal amphotericin (AmBisome). *Br J Haematol* 1998;102:1108-9.
207. Cesaro S, Calore E, Messina C, Zanesco L. Allergic reaction to the liposomal component of liposomal amphotericin B. *Support Care Cancer* 1999;7:284-6.
208. Vaidya SJ, Seydel C, Patel SR, Ortin M. Anaphylactic reaction to liposomal amphotericin B. *Ann Pharmacother* 2002;36:1480-1.
209. Mukhtar M, Aboud M, Kheir M, Bakhiet S, Abdullah N, Ali A, et al. First report on Ambisome-associated allergic reaction in two Sudanese leishmaniasis patients. *Am J Trop Med Hyg* 2011;85:644-5.